WEBINAR VIDEO | Life Sciences Session #9: Hot topics in healthcare tendering
Please join us on 28 November 2022 from 13:30 to 14:30 for our ninth online Life Sciences Session, where Caroline De Mulder and Kirian Claeyé will discuss the latest evolutions in the field of healthcare public procurement and will answer questions such as:
- Is a supplier entitled to indexation of its prices due to the current economic crisis?
- What’s the impact of the new article 71bis of the law of 14 July 1994 concerning the compulsory insurance for medical care and benefits (in Dutch: “ZIV-wet”, in French: “loi AMI”) on tendering for biologicals and biosimilars?
- In which context can suppliers offer benefits to the contracting hospitals?
Contact
Recommended articles
EU General Court bars patient association from challenging medicine authorisation refusal
In Case T‑278/25, the EU General Court recently dismissed as inadmissible a challenge brought by a patient advocacy association against the European Commission’s refusal to renew the conditional marketing authorisation for a treatment against Duchenne muscular dystrophy (DMD). The case is significant because it adds to the case law on contesting Commission decisions relating to the marketing of medicinal products. In this blog post, we look at how the Court came to the conclusion that the association lacked standing to litigate and use this as a basis for an informal categorisation of the existing case law.
Read on
Despite EU harmonisation, Member States may impose authorisation requirements on pharmacy-prepared medicines, rules EU Court of Justice
Under EU pharmaceutical law, certain medicines fall outside the scope of Directive 2001/83/EC (i.e. the Community code on medicinal products for human use). This includes “magistral formulae” (prepared in a pharmacy for an individual patient on prescription) and “officinal formulae” (prepared in a pharmacy in accordance with a pharmacopoeia and supplied directly to that pharmacy’s […]
Read on
EU General Court: technical vaccine data does not have to be disclosed on request
The EU General Court delivered a significant judgment concerning access to documents held by the European Medicines Agency (EMA), this time relating to a conditionally authorised COVID-19 vaccine. This case (T-623/22) serves as an addition to the elaborate case law on the balance between transparency in health matters and the protection of companies' commercial interests. On this (rare) occasion, the commercial interests of the conditional marketing authorisation (‘MA’) holder prevailed, although an appeal is currently pending (C-38/26 P).
Read on